OSI Pharmaceuticals INC.

58 S. Service Road, Suite 110
Melville, NY 11747

USA

Phone: (631) 962-2000
Email: investor_info@osip.com
Web Site: http://www.osip.com/

A. Company Profile

OSI Pharmaceuticals (NASDAQ:OSIP) is one of the world's leading biotech companies. The company focuses exclusively on the discovery, development and commercialization of high-quality, next-generation oncology products.

B. Products

Product Pipelines

1. Novantrone

Novantrone is a synthetic antineoplastic anthracenedione used intravenously as an anti-cancer agent. The product was approved by the FDA in 1987 for leukemia and in 1996 for the relief of pain associated with cancer. It is a DNA-reactive agent that intercalates into DNA through hydrogen bonding, causing crosslinks and strand breaks. Novantrone also interferes with RNA and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA.

2. OSI-027

OSI-027 is a next generation mammalian target of rapamycin (mTOR) kinase inhibitor that inhibits the kinase activity associated with both the TORC1 and TORC2 complexes of mTOR. This dual TORC1 and TORC2 activity differentiates compound from rapamycin and the various related analogs, or rapalogs, that are currently in clinical development in that these molecules only inhibit TORC1 activity.

3. OSI-906

OSI-906 is a potent, selective orally active inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). IGF-1R has been viewed as an important therapeutic target due to its involvement in the growth and proliferation in a variety of human cancers, including colorectal, non-small cell lung, breast and ovarian cancers.

3. OSI-930

OSI-930 is an orally active inhibitor of two validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors.

4.Tarceva

Tarceva (erlotinib HCl), a small molecule inhibitor of the epidermal growth factor receptor, or HER1/EGFR. The protein product of the HER1/EGFR gene is a receptor tyrosine kinase that is overexpressed or mutated in many major solid tumors. HER1/EGFR inhibitors represent an exciting new class of relatively safe and well tolerated anti-cancer agents that may have utility in treating a wide range of cancer patients.